Learn about cystic fibrosis, a genetic disorder that affects the lungs, pancreas, and other organs, and how to treat and live with this chronic disease.
CF is a rare genetic disease found in about 30,000 people in the U.S. If you have CF or are considering testing for it, knowing about the role of genetics in CF can help you make informed decisions about your health care.
If you or your child has just been diagnosed with cystic fibrosis, or your doctor has recommended testing for CF, you may have many questions.
Diagnosing CF is a multistep process. A complete diagnostic evaluation should include a newborn screening, a sweat chloride test, a genetic or carrier test, and a clinical evaluation at a CF Foundation-accredited care center.
Raising a child with cystic fibrosis can bring up many questions because CF affects many aspects of your child’s life. Here you’ll find resources to help you manage your child’s daily needs and find the best possible CF care.
Living with cystic fibrosis comes with many challenges, including medical, social, and financial. By learning more about how you can manage your disease every day, you can ultimately help find a balance between your busy lifestyle and your CF care.
People with CF are living longer, healthier lives than ever before. As an adult with CF, you may reach key milestones you might not have considered. Planning for these life events requires careful thought as you make decisions that may impact your life.
People with cystic fibrosis are living longer and more fulfilling lives, thanks in part to specialized CF care and a range of treatment options.
Cystic Fibrosis Foundation-accredited care centers provide expert care and specialized disease management to people living with cystic fibrosis.
We provide funding for and accredit more than 120 care centers and 53 affiliate programs nationwide. The high quality of specialized care available throughout the care center network has led to the improved length and quality of life for people with CF.
The Cystic Fibrosis Foundation provides standard care guidelines based on the latest research, medical evidence, and consultation with experts on best practices.
As a clinician, you’re critical in helping people with CF maintain their quality of life. We’re committed to helping you partner with patients and their families by providing resources you can use to improve and continue to provide high-quality care.
As part of the Cystic Fibrosis Foundation's mission to help improve the lives of people living with cystic fibrosis, the PSDC initiative taps the CF community to inform key efforts to support the management of daily care.
Your cystic fibrosis care team includes a group of CF health care professionals who partner with you to provide specialized, comprehensive CF care.
Many cystic fibrosis patients and families face complicated issues related to getting the care they need. But CF Foundation Compass makes sure that no one has to do it alone.
For many people with cystic fibrosis, dealing with insurance is as much a part of living with the disease as nebulizers and vests. Many people with CF and their families face issues related to getting the care they need, but no one has to do it alone.
The Cystic Fibrosis Foundation is the world’s leader in the search for a cure for CF and supports a broad range of research initiatives to tackle the disease from all angles.
The CF Foundation offers a number of resources for learning about clinical trials and treatments that are being developed to improve the treatment of cystic fibrosis.
Our understanding of CF continues to evolve as scientists study what causes the disease and how it affects the body. These insights drive the development of new and better treatments and bring us one step closer to a cure.
Researchers, supported by the CF Foundation, have made tremendous advances to improve the health and quality of life of people with CF. We are committed to providing the tools and resources you need to continuously build upon this work.
Our goal is to educate policy makers about the needs of people with cystic fibrosis so that they make smart decisions about CF-related research, treatment, and access to care.
We recognize the value of tapping into the expertise that only people with CF and their families have. We invite you to share insights to help improve and develop programs and services that support the daily lives of people with CF.
Our mission is to find a cure for cystic fibrosis and improve the quality of life for those living with the disease. We can't do it alone. Help us add tomorrows by giving today.
In addition to working for a cure, the CF Foundation supports programs and policies to improve the lives of people with CF. Help us by raising awareness of CF, participating in a fundraising event, or volunteering with your local chapter.
Cystic fibrosis is caused by mutations in the gene responsible for producing the cystic fibrosis transmembrane conductance regulator (CFTR) protein. For this reason, scientists are exploring ways to provide a correct copy of the gene to treat CF.
The cystic fibrosis transmembrane conductance regulator (CFTR) gene contains the instructions for making the CFTR protein. When there is a mutation -- or alteration -- in the genetic instructions, the production of the CFTR protein may be affected. In people with cystic fibrosis, mutations in the CFTR gene can result in no protein, not enough protein, or a protein being made incorrectly. Each of these defects leads to a cascade of problems that affect the lungs and other organs.
Since the discovery of the CFTR gene in 1989, scientists have been trying to find ways to correct the mutations in the gene that cause CF. Although progress was initially slower than anticipated, scientific breakthroughs in the past 10 years have accelerated advances in gene therapy.
Gene therapy is a process in which a new, correct version of the CFTR gene would be placed into the cells in a person's body. Although the mutant copies of the CFTR gene would still be there, the presence of the correct copy would give cells the ability to make normal CFTR proteins.
An advantage of gene therapy is that it could work in any individual with CF, no matter what mutations the person has. A disadvantage of gene therapy is that it can work only in cells that receive the therapy. That means that if gene therapy is used to treat the lungs, it will not help the cells in the digestive system.
Gene therapy cannot repair organ damage that has already occurred. Although gene therapy could reduce the symptoms of CF and prevent further damage from occurring, it cannot fix scarring or other permanent damage that happened prior to the treatment.
Here we will explain three types of gene therapy and the potential they have to treat CF. It is not yet clear which option will work best. The process of physically delivering gene therapy technology to cells is full of challenges. These obstacles would have to be overcome for any gene therapy to work.
In integrating gene therapy, a piece of DNA that contains a correct version of the CFTR gene would be delivered to an individual's cells. The new copy of the CFTR gene would then become a permanent part of their genome, which is the entire set of genetic instructions that is in every cell. This kind of gene therapy is similar to binding a new page into an existing book.
An advantage of an integrating gene therapy is that it is permanent. This means that a person with CF might have to receive the gene therapy only once or a few times in his/her life. A disadvantage is that we may have limited control over where the new copy of the CFTR gene integrates into the genome. The new copy could be inserted into a part of the genome that contains some critical information, like the new page being randomly added to a book and disrupting an important chapter. This means integrating gene therapy could have undesirable side effects, such as increasing the risk of cancer.
A type of integrating gene therapy, known as CAR-T therapies, has already been approved to treat patients with certain kinds of leukemia and lymphoma. An integrating gene therapy to treat CF is being tested in animals, and a clinical trial to test the safety of this therapy in people with CF could happen in the next several years.
In non-integrating gene therapy, a piece of DNA with a correct copy of CFTR is provided to an individual's cells, but the DNA remains separate from the genome. This is like placing a new page between the covers of an existing book without permanently attaching it. Even though the gene therapy does not become part of the genome, the cell can still use the new copy of the CFTR gene to make normal CFTR proteins.
A major advantage of this approach is that the non-integrating gene therapy does not disrupt the rest of the genome, just like adding a new page right under the cover of a book would not disturb the contents of the rest of the book. That means that the risk of side effects, including cancer, is low. A disadvantage of non-integrating gene therapy is that it is not permanent. Because of this, the effect of the gene therapy might last only for several weeks or months. A person with CF would probably need to be treated with the gene therapy repeatedly for it to be effective.
Non-integrating gene therapy has now been approved by the U.S. Food and Drug Administration (FDA) to treat a rare type of blindness, and it has also been shown to work in studies for hemophilia, a blood clotting disorder. It has also been tested in people with CF. In a clinical trial in England, people with CF were given a dose of a non-integrating gene therapy once per month for a year. The study indicated that the CF gene therapy was safe and resulted in a small improvement in lung function.1 Additional work is needed to improve this kind of gene therapy so that it will be more effective at treating CF.
Genes are composed of a series of DNA “letters” that spell out the instructions to make a protein. However, the cell does not use the DNA directly. Instead, the cell makes a working copy of the gene using a similar alphabet called ribonucleic acid (RNA) and uses that working copy to build the protein. Both integrating and non-integrating gene replacement therapies involve giving DNA copies of the CFTR gene to a cell and letting the cell make its own RNA working copies. But, another approach is just to give the cell the RNA copies directly.
The advantage of RNA therapy is that there is no risk of disrupting a person's genome. Using RNA also makes it easier to control the dose.
A disadvantage is that the effects of the RNA therapy might last only for a very short time, such as one or two weeks. This would mean that a patient would have to get repeat doses of the therapy to see improvements.
RNA therapies are being developed to treat a wide range of diseases. A potential RNA therapy for CF is being tested in an early-stage clinical trial to determine safety.
Follow Us On
Help us blaze a trail to better treatments and a cure for CF. Find a clinical trial that may be right for you.
Cystic Fibrosis Foundation
4550 Montgomery Ave.
Suite 1100 N
Bethesda, MD 20814
800-344-4823 (toll free)
Sign up for our emails